Pages that link to "Q37725539"

The following pages link to Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals (Q37725539):

Displaying 37 items.

• Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence (Q26739999) (← links)
• Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (Q26750746) (← links)
• Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? (Q26777994) (← links)
• Treatment of diabetic kidney disease: current and future targets (Q33907249) (← links)
• The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes (Q35951020) (← links)
• Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity (Q36320174) (← links)
• DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid (Q36639293) (← links)
• Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial (Q38377453) (← links)
• The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? (Q38527885) (← links)
• Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner (Q38650405) (← links)
• Obesity and brain inflammation: a focus on multiple sclerosis. (Q38702348) (← links)
• Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease. (Q38713935) (← links)
• The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond (Q38820260) (← links)
• DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control (Q38922177) (← links)
• Anti-inflammatory drugs as promising cardiovascular treatments. (Q39051784) (← links)
• Novel avenues for treating diabetic nephropathy: new investigational drugs. (Q39170387) (← links)
• Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury (Q40666037) (← links)
• The ZDSD rat: a novel model of diabetic nephropathy (Q41965910) (← links)
• Effects of Incretin-Based Therapies on Diabetic Microvascular Complications (Q42366423) (← links)
• Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes (Q42876331) (← links)
• Sitagliptin exerts anti-apoptotic effect in nephrotoxicity induced by cisplatin in rats. (Q46531856) (← links)
• Novel Therapies for Acute Kidney Injury (Q47099705) (← links)
• Cathepsin D plays a role in endothelial-pericyte interactions during alteration of the blood-retinal barrier in diabetic retinopathy. (Q47269696) (← links)
• Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling (Q47899237) (← links)
• High glucose stimulates cell proliferation and Collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling (Q48022832) (← links)
• Sitagliptin Attenuates Endothelial Dysfunction of Zucker Diabetic Fatty Rats: Implication of the Antiperoxynitrite and Autophagy (Q48270894) (← links)
• The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial (Q49592715) (← links)
• DPP4 regulates the inflammatory response in a rat model of febrile seizures (Q51074054) (← links)
• Sitagliptin-Moringa oleifera coadministration did not delay the progression nor ameliorated functional and morphological anomalies in alloxan-induced diabetic nephropathy (Q51743264) (← links)
• DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. (Q53797319) (← links)
• Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes (Q57477167) (← links)
• Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes (Q61814333) (← links)
• Resistance Exercise Training Attenuates the Loss of Endogenous GLP-1 Receptor in the Hypothalamus of Type 2 Diabetic Rats (Q64121402) (← links)
• Crescent-Like Lesions as an Early Signature of Nephropathy in a Rat Model of Prediabetes Induced by a Hypercaloric Diet (Q90692152) (← links)
• Diet-Induced Rodent Models of Diabetic Peripheral Neuropathy, Retinopathy and Nephropathy (Q92813959) (← links)
• Effect of dipeptidyl peptidase-4 inhibitors on complement activation (Q97538758) (← links)
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence (Q102220349) (← links)